「Leishmaniasis」の版間の差分
ナビゲーションに移動
検索に移動
Vaccipedia.admin (トーク | 投稿記録) |
Vaccipedia.admin (トーク | 投稿記録) |
||
(同じ利用者による、間の22版が非表示) | |||
1行目: | 1行目: | ||
+ | {{TM menu}} | ||
+ | |||
==taxonomy== | ==taxonomy== | ||
*phylum ''Sarcomastigophorea'', class ''Zoomastigophorea'', genus ''Leishmania'' | *phylum ''Sarcomastigophorea'', class ''Zoomastigophorea'', genus ''Leishmania'' | ||
5行目: | 7行目: | ||
==morphology== | ==morphology== | ||
*single flagellum | *single flagellum | ||
− | *kinetoplast | + | *kinetoplast - aggregation of DNA |
*similar to ''Trypanosoma'' | *similar to ''Trypanosoma'' | ||
==epidemiology== | ==epidemiology== | ||
*700,000 - 1 mil. new cases per year | *700,000 - 1 mil. new cases per year | ||
− | 20,000-30,000 deaths per year | + | *20,000-30,000 deaths per year |
==life cycle== | ==life cycle== | ||
16行目: | 18行目: | ||
*promastigote - 10-25 μm | *promastigote - 10-25 μm | ||
**with flagellum | **with flagellum | ||
+ | **transform from amastigote inside sandfly midgut | ||
+ | **proliferate inside midgut | ||
+ | **introduced into human skin directly from sandfly midgut during sandfly bite | ||
**phagocytized by macrophage | **phagocytized by macrophage | ||
*amastigote - 2-4 μm | *amastigote - 2-4 μm | ||
**transform from promastigote and propagate inside macrophage | **transform from promastigote and propagate inside macrophage | ||
+ | **propagetes inside macrophage | ||
+ | **parasitized macrophage finally ruptures and let amasitgote out which eventually by sandfly | ||
**transform to promastigote inside sandfly midgut | **transform to promastigote inside sandfly midgut | ||
*simpler than ''Trypanosoma'' | *simpler than ''Trypanosoma'' | ||
24行目: | 31行目: | ||
*host: human, dog, rodent | *host: human, dog, rodent | ||
− | == | + | ===sandfly=== |
− | + | *''Phlebotomus'' spp. | |
+ | **Eurasian | ||
+ | *''Lutzomya'' spp. | ||
+ | **Latin America | ||
+ | *Feed during night | ||
+ | *Bitten site by sandfly produces asymptomatic papule, eventually enlarges to an ulcerated nodule and will be spontaneously healed | ||
+ | |||
+ | ==visceral leishmania== | ||
*most serious | *most serious | ||
*same as Kala-azar | *same as Kala-azar | ||
**Latin "black fever" | **Latin "black fever" | ||
− | *fever | + | *incubation 3 weeks to > 2 years |
− | *weight loss | + | **reason of diversity of incubation unknown |
− | *hepatosplenomegaly | + | *symptoms |
− | *anemia | + | **fever -generally low grade |
− | *50,000-90,000 new cases per year | + | **weight loss |
+ | **hepatosplenomegaly - extremely substantial | ||
+ | ***completely subsides rapidly by treatment | ||
+ | **cough, diarrhea | ||
+ | **anemia, leukopenia, thrombocytopenia | ||
+ | *many patients are asymptomatic and cured spontaneously | ||
+ | **cell-mediated immunity | ||
+ | **mass treatment of asymptomatic patients is very problematic because of lacking of easily taken oral short course drug | ||
+ | *50,000-90,000 new cases reported per year 2004-2008 | ||
+ | *202,200-389,100 new cases estimated per year 2004-2008 - underreporting | ||
**mainly children affected | **mainly children affected | ||
− | **India, Ethiopia, South Sudan, Brazil | + | **India, Ethiopia, South Sudan, Uganda, Brazil |
+ | ***South Asia- decreasing trend towards elimination | ||
+ | ***South Asia- epidemic wave pattern every 15 years | ||
+ | ***East Africa- no decreasing trends | ||
+ | ***East Africa- | ||
+ | ***Latin America- | ||
*''L. donovani'' | *''L. donovani'' | ||
**India, Africa | **India, Africa | ||
41行目: | 69行目: | ||
*''L. infantum'' (formerly ''L. chagasi'' was thought separated species) | *''L. infantum'' (formerly ''L. chagasi'' was thought separated species) | ||
**Mediterranean, China, South America | **Mediterranean, China, South America | ||
− | **dog is reservoir | + | **dog, cattle is reservoir |
+ | |||
+ | ===diagnosis of visceral leishmania=== | ||
+ | *suspect for >2 weeks fever+splenomegaly with geographical relation | ||
+ | *detection of amastigote in smear of bone marrow aspiration, lymph node or spleen aspiration | ||
+ | **sensitivity 93-99% in spleen aspirate, 53-86% in bone marrow aspirate, 53-65% in lymph node aspirate | ||
+ | ***0.1% of life-threatening hemorrhage by spleen aspiration | ||
+ | *culture in NNN media | ||
+ | *immunochromatographical detection of rk39 antigen | ||
+ | **dip stick form | ||
+ | **97-100% sensitivity in Asia, low in Africa | ||
+ | ***reason unkown, possibly the difference of subspecies | ||
+ | **cannot distinguish between active or relapse | ||
+ | **unkown sensitivity in HIV co-infection | ||
+ | *in areas of high HIV prevelence all leischmeniasis patients should be screened for HIV | ||
+ | *PCR | ||
+ | *importance of accurate diagnosis | ||
+ | **clinical features of VL resemble | ||
+ | *DDx | ||
+ | **chronic malaria | ||
+ | **schistosomiasis | ||
+ | **typhoid | ||
+ | **tuberculosis - splenomegaly is rare unless miliary TB | ||
+ | **hematological malignancy | ||
+ | *can be verically transmitted - rare | ||
+ | *Treatment | ||
+ | **to reduce parasite burden | ||
+ | **to improve complication | ||
+ | **to help to induce cell-mediated immunity | ||
+ | *Tx in India | ||
+ | **liposomal AMPH-B | ||
+ | ***+miltefosine | ||
+ | ***+paromomycin | ||
+ | ***+ | ||
+ | **AMPH-B - adherence is diffucult | ||
+ | **miltefosine - adherence is diffucult; now is only for combination with liposomal AMPH-B | ||
+ | **drug interactions | ||
+ | *Tx in East Africa | ||
+ | ** | ||
+ | *Tx for ''L. infantum'' in Latin America | ||
+ | ** | ||
+ | |||
− | + | ===post kala-azar dermal leishmanisis (PKDL)=== | |
*skin manifestation after completion of Tx of visceral leishmaniasis | *skin manifestation after completion of Tx of visceral leishmaniasis | ||
**macular type, papular type, nodular type | **macular type, papular type, nodular type | ||
+ | **possibly 5-10% of VL patients | ||
+ | **incidence 4.8/1000 in India | ||
*''Leishmania'' may be detected from skin specimen in some cases | *''Leishmania'' may be detected from skin specimen in some cases | ||
− | ** | + | **skin is contagious |
+ | **reservoir | ||
+ | *diagnosis | ||
+ | **history of VL | ||
+ | **rK39 | ||
+ | *treatment | ||
+ | **no good evidence | ||
+ | **miltefosine for 12 weeks | ||
− | + | ==cutaneous leishmania== | |
− | |||
*most common | *most common | ||
− | *same as Oriental sore | + | *same as Oriental sore, Chiclero ulcer (in Latin America) |
*papule, nodule → ulcer → scar | *papule, nodule → ulcer → scar | ||
+ | *basically self-limited | ||
*rarely diffuce or disseminated | *rarely diffuce or disseminated | ||
− | * | + | *700,000-1.2 mil. new cases per year |
− | *Afghanistan, Algeria, Brazil, Colombia | + | *90% of cases are from 7 countries |
+ | **Afghanistan, Pakistan, Iran, Syria, Saudi Arabia, Algeria, Brazil, Colombia | ||
+ | ***completely different from VL countries but Brazil | ||
**imported in Texas, US in 2015 | **imported in Texas, US in 2015 | ||
+ | **cutaneous leishmaniasis by ''L. donovani'' is reported in Sri Lanka | ||
+ | **tends to increase in conflict area, mass displacement, military deployment | ||
+ | ***especially in Syria since its civil war | ||
*''L. tropica'', ''L. mexicana'', ''L. amazonensis'' and other species >20 | *''L. tropica'', ''L. mexicana'', ''L. amazonensis'' and other species >20 | ||
+ | *"old world" Africa and South Asia | ||
+ | *"new world" Latin America | ||
+ | *''Rhombomys opimus'' (great gerbil) is primary reservoir | ||
+ | |||
+ | ===transmission=== | ||
+ | *anthroponotic (''L. tropica'') or zoonotic (other species) | ||
+ | *skin contact with active lesion innocuous | ||
+ | *risk factors | ||
+ | **poor quality housing | ||
+ | **male | ||
+ | **younger age <15 y/o | ||
+ | **proximity to forest | ||
+ | **domestic dog ownership | ||
+ | **sleeping in temporary shelters | ||
+ | |||
+ | ===clinical features=== | ||
+ | *no life threatening | ||
+ | *significant cosmetic morbidity | ||
+ | **stigmatization | ||
+ | *old world | ||
+ | **dryer, warty, scaly | ||
+ | *new world | ||
+ | **wet, ulcerative | ||
+ | **lymphadenopathy | ||
+ | |||
+ | ====diffuse cutaneous leishmaniasis==== | ||
+ | *rare form of CL | ||
+ | *nodular, papular | ||
+ | |||
+ | ====disseminated CL==== | ||
+ | *rare form of CL | ||
+ | *>10 mixed type skin lesions | ||
+ | *in immunocompromised host | ||
+ | |||
+ | ====leishmania recidivans==== | ||
+ | *by ''L. tropica'' | ||
+ | *new lesions encircling years-old scar | ||
− | ===mucocutaneous leishmania=== | + | ===diagnosis of cutaneous leishmaniasis=== |
+ | *smear of fine needle aspirate or biopsy of skin lesion | ||
+ | **specimen from ulcer margin is the highest yield | ||
+ | **fine needle aspiration cytology is generally better | ||
+ | *serological test is of no use; low sensitivity and variable specificity | ||
+ | *NAAT is available | ||
+ | |||
+ | ====DDx of CL==== | ||
+ | **staphylococcal infection | ||
+ | **streptococcal infection | ||
+ | **mycobacterial ulcer | ||
+ | **fungal ulcer | ||
+ | **cancer | ||
+ | **sarcoidosis | ||
+ | **tropical ulcer - | ||
+ | |||
+ | ==mucocutaneous leishmania== | ||
+ | *only in new world CL | ||
+ | **Bolivia, Brazil, Peru | ||
+ | *same as Espundia, white leprosy | ||
+ | *lyphatic or hematogenous dissemination to mucosa in mouth and/or upper respiratory tract, resulted in destruction and deformity of nose, palate, pharynx | ||
+ | *''L. braziliensis'', ''L. panamensis'' | ||
+ | *progressive ever without treatment | ||
+ | *secondary bacterial infection | ||
+ | *worsening nasal congestion, epistaxis or discharge common | ||
+ | *permanent disfigurement of face | ||
+ | **cleft palate, nasal septum destruction, "Tapir" nose | ||
+ | |||
+ | ===diagnosis of mucocutaneous leishmaniasis=== | ||
+ | *leishmania is scarce in mucosal lesion | ||
+ | **strong local immune response | ||
+ | *serology or molecular | ||
==emerging novel leishmaniasis== | ==emerging novel leishmaniasis== | ||
*in Thailand | *in Thailand | ||
*''L. siamensis'', ''L. martiniquensis'' | *''L. siamensis'', ''L. martiniquensis'' | ||
+ | |||
+ | ==treatment== | ||
+ | *majority spontaneously healed in 2-15months | ||
+ | *distinguish simple or complex | ||
+ | **complex - | ||
+ | *new world needs more to identify species to anticipate of progression to mucocutaneous CL | ||
+ | |||
+ | |||
+ | *pentavalent antimonial | ||
+ | **meglumine antimoniate | ||
+ | **sodium stibogluconate | ||
+ | *amphotericin B | ||
+ | **liposomal amphotericin B | ||
+ | *paromomycin | ||
+ | *pentamidine | ||
+ | *miltefosine | ||
+ | |||
+ | |||
+ | *cryotherapy | ||
+ | **liquid nitrogen | ||
+ | *thermotherapy | ||
+ | **40-42℃ for 3min. | ||
+ | ***50℃ for 30 sec. | ||
+ | **make second degree burn | ||
+ | |||
+ | |||
+ | *topical application | ||
+ | |||
+ | ==vaccine== | ||
+ | *no human vaccine | ||
+ | *canine vaccine has been rolled out | ||
+ | *"leishmanization" in Uzbeskistan | ||
+ | **intradermal inoculation of live wild strain of ''L. major'' | ||
+ | |||
+ | ==control== | ||
+ | *case detection and treatment for anthroponotic leishmaniasis | ||
+ | *vector control for sandfly-borne leishmaniasis | ||
+ | *destruction of burrows of great gerbil | ||
+ | |||
+ | ==GHIT Fund== | ||
+ | Global Health Innovative Technology Fund | ||
+ | *supported by Japanese Government |
2022年10月15日 (土) 21:41時点における最新版
Navigation Menu |
General issues of Vaccine | |||||||
---|---|---|---|---|---|---|---|
|
General issues of Travel med. | ||||||||
---|---|---|---|---|---|---|---|---|
|
Immunology | |||||||
---|---|---|---|---|---|---|---|
|
Epi & Stats | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Virus | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
COVID-19 | |||||
---|---|---|---|---|---|
|
Bacteria | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Rickettsia | |||||
---|---|---|---|---|---|
|
Protozoa | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Fungi | |||||||
---|---|---|---|---|---|---|---|
|
Nematode (roundworm) | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Trematode (fluke, distoma) | |||||||
---|---|---|---|---|---|---|---|
|
Cestode (tapeworm) | ||||||
---|---|---|---|---|---|---|
|
Medical Zoology | ||||||||
---|---|---|---|---|---|---|---|---|
|
目次
taxonomy
- phylum Sarcomastigophorea, class Zoomastigophorea, genus Leishmania
- Plasmodium belongs to phylum Apicomplexa
morphology
- single flagellum
- kinetoplast - aggregation of DNA
- similar to Trypanosoma
epidemiology
- 700,000 - 1 mil. new cases per year
- 20,000-30,000 deaths per year
life cycle
- parasitize in human macrophage
- promastigote - 10-25 μm
- with flagellum
- transform from amastigote inside sandfly midgut
- proliferate inside midgut
- introduced into human skin directly from sandfly midgut during sandfly bite
- phagocytized by macrophage
- amastigote - 2-4 μm
- transform from promastigote and propagate inside macrophage
- propagetes inside macrophage
- parasitized macrophage finally ruptures and let amasitgote out which eventually by sandfly
- transform to promastigote inside sandfly midgut
- simpler than Trypanosoma
- vector: sandfly
- host: human, dog, rodent
sandfly
- Phlebotomus spp.
- Eurasian
- Lutzomya spp.
- Latin America
- Feed during night
- Bitten site by sandfly produces asymptomatic papule, eventually enlarges to an ulcerated nodule and will be spontaneously healed
visceral leishmania
- most serious
- same as Kala-azar
- Latin "black fever"
- incubation 3 weeks to > 2 years
- reason of diversity of incubation unknown
- symptoms
- fever -generally low grade
- weight loss
- hepatosplenomegaly - extremely substantial
- completely subsides rapidly by treatment
- cough, diarrhea
- anemia, leukopenia, thrombocytopenia
- many patients are asymptomatic and cured spontaneously
- cell-mediated immunity
- mass treatment of asymptomatic patients is very problematic because of lacking of easily taken oral short course drug
- 50,000-90,000 new cases reported per year 2004-2008
- 202,200-389,100 new cases estimated per year 2004-2008 - underreporting
- mainly children affected
- India, Ethiopia, South Sudan, Uganda, Brazil
- South Asia- decreasing trend towards elimination
- South Asia- epidemic wave pattern every 15 years
- East Africa- no decreasing trends
- East Africa-
- Latin America-
- L. donovani
- India, Africa
- anthroponotic = maintained in human-to-human infection
- L. infantum (formerly L. chagasi was thought separated species)
- Mediterranean, China, South America
- dog, cattle is reservoir
diagnosis of visceral leishmania
- suspect for >2 weeks fever+splenomegaly with geographical relation
- detection of amastigote in smear of bone marrow aspiration, lymph node or spleen aspiration
- sensitivity 93-99% in spleen aspirate, 53-86% in bone marrow aspirate, 53-65% in lymph node aspirate
- 0.1% of life-threatening hemorrhage by spleen aspiration
- sensitivity 93-99% in spleen aspirate, 53-86% in bone marrow aspirate, 53-65% in lymph node aspirate
- culture in NNN media
- immunochromatographical detection of rk39 antigen
- dip stick form
- 97-100% sensitivity in Asia, low in Africa
- reason unkown, possibly the difference of subspecies
- cannot distinguish between active or relapse
- unkown sensitivity in HIV co-infection
- in areas of high HIV prevelence all leischmeniasis patients should be screened for HIV
- PCR
- importance of accurate diagnosis
- clinical features of VL resemble
- DDx
- chronic malaria
- schistosomiasis
- typhoid
- tuberculosis - splenomegaly is rare unless miliary TB
- hematological malignancy
- can be verically transmitted - rare
- Treatment
- to reduce parasite burden
- to improve complication
- to help to induce cell-mediated immunity
- Tx in India
- liposomal AMPH-B
- +miltefosine
- +paromomycin
- +
- AMPH-B - adherence is diffucult
- miltefosine - adherence is diffucult; now is only for combination with liposomal AMPH-B
- drug interactions
- liposomal AMPH-B
- Tx in East Africa
- Tx for L. infantum in Latin America
post kala-azar dermal leishmanisis (PKDL)
- skin manifestation after completion of Tx of visceral leishmaniasis
- macular type, papular type, nodular type
- possibly 5-10% of VL patients
- incidence 4.8/1000 in India
- Leishmania may be detected from skin specimen in some cases
- skin is contagious
- reservoir
- diagnosis
- history of VL
- rK39
- treatment
- no good evidence
- miltefosine for 12 weeks
cutaneous leishmania
- most common
- same as Oriental sore, Chiclero ulcer (in Latin America)
- papule, nodule → ulcer → scar
- basically self-limited
- rarely diffuce or disseminated
- 700,000-1.2 mil. new cases per year
- 90% of cases are from 7 countries
- Afghanistan, Pakistan, Iran, Syria, Saudi Arabia, Algeria, Brazil, Colombia
- completely different from VL countries but Brazil
- imported in Texas, US in 2015
- cutaneous leishmaniasis by L. donovani is reported in Sri Lanka
- tends to increase in conflict area, mass displacement, military deployment
- especially in Syria since its civil war
- Afghanistan, Pakistan, Iran, Syria, Saudi Arabia, Algeria, Brazil, Colombia
- L. tropica, L. mexicana, L. amazonensis and other species >20
- "old world" Africa and South Asia
- "new world" Latin America
- Rhombomys opimus (great gerbil) is primary reservoir
transmission
- anthroponotic (L. tropica) or zoonotic (other species)
- skin contact with active lesion innocuous
- risk factors
- poor quality housing
- male
- younger age <15 y/o
- proximity to forest
- domestic dog ownership
- sleeping in temporary shelters
clinical features
- no life threatening
- significant cosmetic morbidity
- stigmatization
- old world
- dryer, warty, scaly
- new world
- wet, ulcerative
- lymphadenopathy
diffuse cutaneous leishmaniasis
- rare form of CL
- nodular, papular
disseminated CL
- rare form of CL
- >10 mixed type skin lesions
- in immunocompromised host
leishmania recidivans
- by L. tropica
- new lesions encircling years-old scar
diagnosis of cutaneous leishmaniasis
- smear of fine needle aspirate or biopsy of skin lesion
- specimen from ulcer margin is the highest yield
- fine needle aspiration cytology is generally better
- serological test is of no use; low sensitivity and variable specificity
- NAAT is available
DDx of CL
- staphylococcal infection
- streptococcal infection
- mycobacterial ulcer
- fungal ulcer
- cancer
- sarcoidosis
- tropical ulcer -
mucocutaneous leishmania
- only in new world CL
- Bolivia, Brazil, Peru
- same as Espundia, white leprosy
- lyphatic or hematogenous dissemination to mucosa in mouth and/or upper respiratory tract, resulted in destruction and deformity of nose, palate, pharynx
- L. braziliensis, L. panamensis
- progressive ever without treatment
- secondary bacterial infection
- worsening nasal congestion, epistaxis or discharge common
- permanent disfigurement of face
- cleft palate, nasal septum destruction, "Tapir" nose
diagnosis of mucocutaneous leishmaniasis
- leishmania is scarce in mucosal lesion
- strong local immune response
- serology or molecular
emerging novel leishmaniasis
- in Thailand
- L. siamensis, L. martiniquensis
treatment
- majority spontaneously healed in 2-15months
- distinguish simple or complex
- complex -
- new world needs more to identify species to anticipate of progression to mucocutaneous CL
- pentavalent antimonial
- meglumine antimoniate
- sodium stibogluconate
- amphotericin B
- liposomal amphotericin B
- paromomycin
- pentamidine
- miltefosine
- cryotherapy
- liquid nitrogen
- thermotherapy
- 40-42℃ for 3min.
- 50℃ for 30 sec.
- make second degree burn
- 40-42℃ for 3min.
- topical application
vaccine
- no human vaccine
- canine vaccine has been rolled out
- "leishmanization" in Uzbeskistan
- intradermal inoculation of live wild strain of L. major
control
- case detection and treatment for anthroponotic leishmaniasis
- vector control for sandfly-borne leishmaniasis
- destruction of burrows of great gerbil
GHIT Fund
Global Health Innovative Technology Fund
- supported by Japanese Government